Management of multiple endocrine neoplasia syndrome type 2 families in association with rare germline mutations of the RET proto-oncogene;Management von familien mit einem multiplen endokrinen neoplasie-syndrom typ 2 in assoziation mit seltenen keimbahnmutationen des RET-protoonkogens

Klinische Padiatrie

Volumn 216, Issue 5, 2004, Pages 270-276

  Fitze, Guido ^a   Saeger, H D ^a   Roesner, D ^a   Schackert, H K ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Endocrinology; Mutation; Prophylaxis; RET Proto oncogene; Surgery

Indexed keywords

ADRENALIN; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; HOMOVANILLIC ACID; NORADRENALIN; PARATHYROID HORMONE; PENTAGASTRIN; VANILMANDELIC ACID;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENE MUTATION; GENOTYPE; HETEROZYGOTE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HYPERPARATHYROIDISM; MALE; NEUROFIBROMATOSIS; ONCOGENE RET; PENETRANCE; PHENOTYPE; PHEOCHROMOCYTOMA; SCHOOL CHILD; SIPPLE SYNDROME; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY;

ADOLESCENT; ADULT; BASE SEQUENCE; CARCINOMA, MEDULLARY; CHILD; CODON; FEMALE; GENOTYPE; GERM-LINE MUTATION; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B; PEDIGREE; PHENOTYPE; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RET; RECEPTOR PROTEIN-TYROSINE KINASES; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 4644221711     PISSN: 03008630     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-44902     Document Type: Article

References (33)

1. Bachmann K-D, Bartram CR, Chang-Claude J, Fonatsch Ch, Propping P. Richtlinien zur Diagnostik der genetischen Disposition für Krebserkrankungen. Deutsches Ärzteblatt 1998; 95: B1120-B1127
2. Baloh RH, Tansey MG, Lampe PA, Fahrner TJ, Enomoto H, Simburger KS, Leitner ML, Araki T, Johnson EM Jr, Milbrandt J. Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRα3-RET receptor complex. Neuron 1998; 21: 1291-1302
3. Berndt I, Reuter M, Sailer B, Frank-Raue K, Groth P, Grußendorf M, Raue F, Ritter M, Höppner W. A new Hot spot for mutations in the RET Protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2 A. J Clin Endocrinol Metab 1998; 83: 770-774
4. Bolino A, Schuffenecker I, Luo Y, Seri M, Silengo M, Tocco T, Chabrier G, Houdet C, Murat A, Schlumberger M, Tourniaire J, Lenoir GM, Romeo G. RET mutations in exons 13 and 14 of FMTC patients. Oncogene 1995; 10: 2415-2419
5. Borrello MG, Smith DP, Pasini B, Bongarzone I, Greco A, Lorenzo MJ, Arighi E, Miranda C, Eng C, Alberti L, Bocciardi R, Mondellini P, Scopsi L, Romeo G, Ponder BAJ, Pierotti MA. RET activation by germline MEN2A and MEN2B mutations. Oncogene 1995; 11: 2419-2427
6. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A, Lips CJM, Lombardi G, Manelli M, Pacini F, Ponder BAJ, Raue F, Skogseid B, Tamburano G, Thakker RV, Thompson NW, Tomasetti P, Tonelli F, Wells SAJr, Marx SJ. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001; 86: 5658-5671
7. Ceccherini I, Hofstra RMW, Luo Y, Stulp RP, Barone V, Stelwagen T, Bocciardi R, Nijveen H, Bolino A, Seri M, Ronchetto P, Pasini B, Bozzano M, Buys CHCM, Romeo G. DNA polymorphisms and conditions for SSCP analysis of the 20 exons of the ret proto-oncogene. Oncogene 1994; 9: 3025-3029
8. Dralle H, Gimm O, Simon D, Frank-Raue K, Görtz G, Niederle B, Wahl RA, Koch B, Walgenbach S, Hampel R, Ritter MM, Spelsberg F, Heiss A, Hinze R, Höppner W. Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian Experiance. World J Surg 1998; 22: 744-751
9. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Laimore TC, Howe JR, Moley JF, Goodfellow P, Wells SA. Mutations in the RET proto-oncogene are associated with MEN2A and FMTC. Hum Mol Genet 1993; 2: 851-856
10. Eng Ch, Mulligan LM. Mutation of the RET Proto-Oncogene in the Multiple Endocrine Neoplasia Type 2 Syndromes. Related Sporadic Tumours, and Hirschsprung Disease. Hum Mutat 1997; 9: 97-109
11. Fitze G, Schreiber M, Kuhlisch E, Schackert HK, Roesner D. Association of RET protooncogene codon 45 polymorphism with Hirschsprung disease. Am J Hum Genet 1999; 65: 1469-1473
12. Fitze G, Cramer J, Ziegler A, Schierz M, Schreiber M, Kuhlisch E, Roesner D, Schackert HK. Association between C135G/A genotypes and RET proto-oncogene germline mutations and phenotype of Hirschsprung's disease. Lancet 2002; 359: 1200-1205
13. Gimm O, Dralle H. C-cell cancer - prevention and treatment. Langenbecks Arch Surg 1999; 384: 16-23
14. Hinze R, Holzhausen HJ, Gimm O, Dralle H, Rath F-W. Primary heredity medullary thyroid carcinoma - C-cell morphology and correlation with preoperative calcitonin levels. Virchows Arch 1998; 433: 203-208
15. Hofstra RM, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y, Pasini B, Höppener JWM, Ploos van Amstel HK, Romeo G, Lips CJM, Buys CHCM. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994; 367: 375-376
16. Hotz HG, Runkel NSF, Frank-Raue K, Raue F, Buhr HJ. Prophylactic thyroidectomy in MEN HA: does the calcitonin level correlate with tumor spread? Langenbecks Arch Surg 1998; 383: 170-173
17. Huang SC, Koch CA, Vortmeyer AO, Pack SD, Lichtenauer DU, Mannan P, Lubensky IA, Chrousos GP, Gagel RF, Pacak K, Zhuang Z. Duplication of the mutant RET allele in trisomy 10 or loss of the wild-type allele in multiple enocrine neoplasia type 2-associated pheochromocytoma. Cancer Res 2000; 60: 6223-6226
18. Kotzbauer FT, Lampe PA, Heuckeroth RO, Golden JP, Creedom DJ, Johnson EM, Milbrandt J. Neurturin, a relative of glial cell line-derived neurotrophic factor. Nature 1996; 384: 467-470
19. Lin LF, Doferty DH, Lile JD, Bektesh S, Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993; 260: 1130-1132
20. Machens A, Gimm O, Hinze R, Höppner W, Boehm BO, Dralle H et al. Genotype-phenotype correlation in hereditary medullary thyroid carcinoma: Oncological features and biochemical properties. J Clin Endocrinol Metab 2001; 86: 1104-1109
21. Marsh DJ, McDowall D, Hyland VJ, Andrew SD, Schnitzler M, Gaskin EL, Nevell DF, Diamond T, Delbridge L, Clifton-Bligh P, Robinson BG. The identification of false-positive response to the pentagastrin stimulation test in RET mutation negative members of MEN2A families. Clin Endocrinol 1996; 44: 213-220
22. Marsh DJ, Andrew SD, Eng C, Learoyd DL, Capes AG, Pojer R, Richardson A-L, Houghton C, Mulligan LM, Ponder BAJ, Robinson BG. Germline and somatic mutations in an Oncogene: RET mutations in inherited medullary thyroid carcinoma. Cancer Res 1996; 56: 1241-1243
23. Mulligan LM, Kwok JBJ, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Clayton D, Mole SE, Moore JK, Papi L, Ponder MA, Telenius H, Tunnacliffe A, Ponder BAJ. Germline mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2 A. Nature 1993; 363: 458-460
24. Mulligan LM, Eng C, Attie T, Lyonnet S, Marsh D, Hyland VJ, Robinson BG, Frilling A, Verellen-Dumoulin C, Safar A, Venter DJ, Munnich A, Ponder BAJ. Diverse phenotype associated with exon 10 mutations of the RET proto-oncogene. Hum Mol Genet 1994; 3: 2163-2167
25. Mulligan LM, Eng Ch, Healey CS, Clayton D, Kwok JBJ, Gardner E, Ponder MA, Frilling A, Jackson CE, Lehnen H, Neumann HPH, Thibodeau SN, Ponder BAJ. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN2A and FMTC. Nature Genet 1994; 6: 70-74
26. Niccoli-Sire P, Murat A, Rohmer V, Franc S, Chabrier G, Baldet L, Maes B, Savagner F, Giraud S, Bezieau S, Kottler ML, Morange S, Conte-Devolx B. Familial medullary thyroid carcinoma with noncysteine RET mutations: Phenotype-genotype relationship in a large series of patients. J Clin Endocrinol Metab 2001; 86: 3747-3753
27. Pasini A, Geneste O, Legrand P, Schlumberger M, Rossel M, Fournier L, Rudkin BB, Schuffenecker I, Lenoir GM, Billaud M. Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain. Oncogene 1997; 15: 393-402
28. Roher HD, Simon D, Goretzki PE, Höppner W, Lederbogen S, Seppel T. Die prophylaktische Radikaloperation des C-Zell-Karzinoms beim MEN-11-Syndrom auf der Grundlage des genetischen Screening. Chirurg 1995; 66: 1196-1202
29. Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, Fusco A, Vecchio G, Matoskova B, Kraus MH, Di Fiore PP. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 1995; 267: 381-383
30. Schuffenecker I, Ginet N, Goldgar D, Eng C, Chambe B, Boneu A, Houdent C, Pallo D, Schlumberger M, Thivolet C, Lenoir GM. Prevalence and parental origin of de novo RET mutations in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma. Le Groupe d'Etude des Tumeurs a Calcitonine. Am J Hum Genet 1997; 60: 233-237
31. Seri M, Yin L, Barone V, Bolino A, Celli I, Bocciardi R, Pasini B, Ceccherini I, Lerone M, Kristofferson U, Larsson LT, Casasa JM, Cass DT, Abramowicz MJ, Vanderwinden JM, Kravcenkiene I, Baric I, Silengo M, Martuciello G, Romeo G. Frequency of RET mutations in long- and short-segment Hirschsprung disease. Hum Mutat 1997; 9: 243-249
32. Trupp M, Arenas E, Fainzilber M, Nilsson A-S, Sleber B-A, Grigoriou M, Kilkenny C, Salazar-Grueso E, Pachnis V, Arumae U, Sariola H, Saarma M, Ibanez CF. Functional receptor for GDNF encoded by the c-RET proto-oncogene. Nature 1996; 381: 785-789
33. Wells SA, Chi DD, Toshima D, Dehner LP, Coffin CM, Darton B, Ivanovitch JL, DeBenedetti MK, Dilley WG, Moley JF, Norton JA, Donis-Keller H. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2 A. Ann Surg 1994; 200: 237-250